PR
PSP Research Portfolio holdings
AUM
$114M
This Fund
S&P 500
1 Year Est. Return
–
AUM
$114M
AUM Growth
–
Holding
85
Top Buys
| 1 | +$70.3M | |
| 2 | +$699K | |
| 3 | +$656K | |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
+$601K |
| 5 |
Mineralys Therapeutics
MLYS
|
+$594K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 38.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Immunocore
IMCR
$1.7B
| $501K | 0.44% |
+14,424
|
|
||
77
Kymera Therapeutics
KYMR
$7.28B
| $494K | 0.43% |
+6,348
|
|
||
|
UPB
78
Upstream Bio Inc
UPB
$428M
| $479K | 0.42% |
+17,634
|
|
||
79
Olema Pharmaceuticals
OLMA
$1.98B
| $477K | 0.42% |
+19,063
|
|
||
80
Cogent Biosciences
COGT
$6.49B
| $470K | 0.41% |
+13,233
|
|
||
81
Structure Therapeutics
GPCR
$4.7B
| $467K | 0.41% |
+6,719
|
|
||
|
DFTX
82
Definium Therapeutics
DFTX
$1.72B
| $467K | 0.41% |
+34,841
|
|
||
83
Arrowhead Research
ARWR
$8.92B
| $444K | 0.39% |
+6,689
|
|
||
|
ALMS
84
Alumis Inc
ALMS
$3.5B
| $427K | 0.37% |
+43,769
|
|
||
85
Dyne Therapeutics
DYN
$2.56B
| $421K | 0.37% |
+21,535
|
|